Aim: To characterize by multimodal approach the phenotype of patients from a 3 generations pedigree, affected by autosomal dominant cone-rod dystrophy (CRD), found to carry a novel pathogenic variant in the cone-rod homeobox-containing (CRX) gene. Methods: Examination of the adult patients included the following tests: visual acuity, multicolour imaging, spectral domain optical coherence tomography (SD-OCT), fundus autofluorescence (FAF) and OCT angiography (OCT-A) recordings. In a 2.5-year-old child, cycloplegic refraction, fundoscopy, ocular motility evaluation and electrophysiological exams were performed. Next Generation Sequencing of patients’ DNA has been carried out. Results: A novel CRX pathogenic variant has been identified in our patients. The 2.5-year-old child in the third generation was found to have inherited the variant, with no clinical signs of the condition, but electroretinographic abnormalities in the scotopic component. In the adult patients, diffuse atrophy of the retinal pigment epithelium/photoreceptor complex in the macular region was evident at the OCT and FAF, while OCT-A showed choriocapillaris density reduction. Conclusions: Multimodal study allowed the characterization of a peculiar form of CRD. The novel pathogenic variant seems to have a different effect on the phenotype if compared with a previously described similar one, giving an insight into the pathogenic mechanism of CRX-related retinal dystrophies and offering valuable information that could lead to the development of possible future therapies.

1.
Hamel CP: Cone rod dystrophies. Orphanet J Rare Dis 2007; 2: 7.
2.
RetNet, http://www.sph.uth.tmc.edu/RetNet/.
3.
Evans K, Fryer A, Inglehearn C, Duvall-Young J, Whittaker JL, Gregory CY, Butler R, Ebenezer N, Hunt DM, Bhattacharya S: Genetic linkage of cone-rod retinal dystrophy to chromosome 19q and evidence for segregation distortion. Nat Genet 1994; 6: 210–213.
4.
Gregory CY, Evans K, Whittaker JL, Fryer A, Weissenbach J, Bhattacharya SS: Refinement of the cone-rod retinal dystrophy locus on chromosome 19q. Am J Hum Genet 1994; 55: 1061–1063.
5.
Freund CL, Gregory-Evans CY, Furukawa T, Papaioannou M, Looser J, Ploder L, Bellingham J, Ng D, Herbrick JA, Duncan A, Scherer SW, Tsui LC, Loutradis-Anagnostou A, Jacobson SG, Cepko CL, Bhattacharya SS, McInnes RR: Cone-rod dystrophy due to mutations in a novel photoreceptor specific homeobox gene (CRX) essential for maintenance of the photoreceptor. Cell 1997; 91: 543–553.
6.
Furukawa T, Morrow EM, Cepko CL: Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation. Cell 1997; 91: 531–541.
7.
Kimura A, Singh D, Wawrousek EF, Kikuchi M, Nakamura M, Shinohara T: Both PCE-1/RX and OTX/CRX interactions are necessary for photoreceptor-specific gene expression. J Biol Chem 2000; 275: 1152–1160.
8.
Huang L, Xiao X, Li S, Jia X, Wang P, Guo X, Zhang Q: CRX variants in cone-rod dystrophy and mutation overview. Biochem Biophys Res Commun 2012; 498–503.
9.
Stone EM: Leber congenital amaurosis – a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol 2007; 144: 791–811.
10.
Rivolta C, Berson EL, Dryja TP: Dominant Leber congenital amaurosis, cone-rod degeneration, and retinitis pigmentosa caused by mutant versions of the transcription factor CRX. Hum Mutat 2001; 18: 488–498.
11.
Kitiratschky VB, Nagy D, Zabel T, Zrenner E, Wissinger B, Kohl S, Jägle H: Cone and cone-rod dystrophy segregating in the same pedigree due to the same novel CRX gene mutation. Br J Ophthalmol 2008; 92: 1086–1091.
12.
Ruzycki PA, Tran NM, Kefalov VJ, Kolesnikov AV, Chen S: Graded gene expression changes determine phenotype severity in mouse models of CRX-associated retinopathies. Genome Biol 2015; 16: 171.
13.
Tran NM, Chen S: Mechanisms of blindness: animal models provide insight into distinct CRX-associated retinopathies. Dev Dyn 2014; 243: 1153–1166.
14.
Tran NM, Zhang A, Zhang X, Huecker JB, Hennig AK, Chen S: Mechanistically distinct mouse models for CRX-associated retinopathy. PLoS Genet 2014; 10:e1004111.
15.
Schweingruber C, Rufener SC, Zünd D, Yamashita A, Mühlemann O: Nonsense-mediated mRNA decay – mechanisms of substrate mRNA recognition and degradation in mammalian cells. Biochim Biophys Acta 2013; 1829: 612–623.
16.
Blaauwgeers HG, Holtkamp GM, Rutten H, et al: Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155: 421–428.
17.
Giani A, Pellegrini M, Carini E, Peroglio Deiro A, Bottoni F, Staurenghi G: The dark atrophy with indocyanine green angiography in stargardt disease. Invest Ophthalmol Vis Sci 2012; 53: 3999–4004.
18.
Hennig AK, Peng GH, Chen S: Regulation of photoreceptor gene expression by Crx-associated transcription factor network. Brain Res 2008; 1192: 114–133.
19.
Chen S, Wang QL, Nie Z, Sun H, Lennon G, Copeland NG, Gilbert DJ, Jenkins NA, Zack DJ: Crx, a novel Otx-like paired-homeodomain protein, binds to and transactivates photoreceptor cell-specific genes. Neuron 1997; 19: 1017–1030.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.